扶正解毒方联合吉西他滨和顺铂对晚朔非小细胞”，御泉患者I细JJL亚群和 血清月．!‘瘤标志物的影l响.

To investigate the effect of Fuzheng Jiedu formula combined with gemcitabine and cisplatin on T cell sub- sets and serum tumor markers in patients with advanced non-small cell lung cancer (NSCLC). Methods: 80 patients with advanced NSCLC who were admitted to our hospital from March 2017 to December 2018 were selected, patients were divided into control group (n=40, treatmented with gemcitabine and cisplatin) and study group (n=40, treatmented with Fuzheng Jiedu Fang combined with gemcitabine and cisplatin) according to the random number method. The therapeutic effect, T cell subsets and serum tumor markers were com- pared between the two groups, and the adverse reactions of two groups were recorded. Results: The total clinical effective rate of the study group at 4 cycles after treatment was higher than that of the control group (P<0.05). CD3+, CD4+, CD4+ /CD8+ in the two groups at 4 cycles after treatment decreased compared with those before treatment, but the study group was higher than the control group (P<0.05). CD8+ in the two groups at 4 cycles after treatment increased compared with that before treatment, but the study group was lower than the control group (P<0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199) of the two groups at 4 cycles after treatment were lower than those before treatment, the study group was lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Fuzheng Jiedu formula combined with gemcitabine and cisplatin in the treatment of advanced NSCLC patients, the effect is good, which can effectively prevent the progress of disease, reduce the immunosuppression, and has a good safety, and which has a certain clinical ap- plication value. [ABSTRACT FROM AUTHOR]